Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
Linder M, Ekbom A, Brobert G, Vogtländer K, Balabanova Y, Becattini C, Carrier M, Cohen AT, Coleman CI, Khorana AA, Lee AYY, Psaroudakis G, Abdelgawwad K, Rivera M, Schaefer B, Giunta DH. Linder M, et al. Among authors: vogtlander k. J Thromb Thrombolysis. 2024 May 12. doi: 10.1007/s11239-024-02992-1. Online ahead of print. J Thromb Thrombolysis. 2024. PMID: 38735015
Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study.
Öngen HG, Akdeniz B, Düzenli MA, Chernyavsky A, Dabar G, Idrees M, Khludeeva E, Kültürsay H, Lukianchikova V, Martynyuk T, Moğulkoç N, Mukarov MA, Mutlu B, Okumuş G, Omarov A, Önen ZP, Sakkijha H, Shostak N, Simakova M, Tokgözoğlu L, Tomskaya T, Yildirim H, Zateyshchikov D, Hechenbichler K, Kessner S, Schauerte I, Turgut N, Vogtländer K, Aldalaan A; CTEPH EMEA Registry Investigators. Öngen HG, et al. Among authors: vogtlander k. Drugs Real World Outcomes. 2024 Mar;11(1):149-165. doi: 10.1007/s40801-023-00407-w. Epub 2024 Feb 21. Drugs Real World Outcomes. 2024. PMID: 38381283 Free PMC article.
Identifying the highest risk vascular patients: Insights from the XATOA registry.
Anand SS, Aboyans V, Bosch J, Debus S, Gay A, Patel MR, Vogtländer K, Welsh RC, Zeymer U, Fox KAA; XATOA Steering Committee. Anand SS, et al. Among authors: vogtlander k. Am Heart J. 2024 Mar;269:191-200. doi: 10.1016/j.ahj.2024.01.001. Epub 2024 Jan 12. Am Heart J. 2024. PMID: 38218425 Free article.
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.
Fox KAA, Aboyans V, Debus ES, Zeymer U, Cowie MR, Patel M, Welsh RC, Bosch J, Gay A, Vogtländer K, Anand SS. Fox KAA, et al. Among authors: vogtlander k. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):825-836. doi: 10.1093/ehjcvp/pvac028. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 35594542 Clinical Trial.
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
Fox KAA, Anand SS, Aboyans V, Cowie MR, Debus ES, Zeymer U, Monje D, Vogtländer K, Lawatscheck R, Gay A. Fox KAA, et al. Among authors: vogtlander k. Am Heart J. 2020 Apr;222:166-173. doi: 10.1016/j.ahj.2020.01.015. Epub 2020 Jan 28. Am Heart J. 2020. PMID: 32092505 Clinical Trial.
12 results